Weight-loss drugs like Ozempic may disrupt medical imaging results, study finds
Research indicates that GLP-1 weight-loss drugs like Ozempic and Wegovy may interfere with PET-CT scans, causing abnormal FDG uptake patterns that could lead to misdiagnosis, unnecessary tests, and treatment delays. Medical professionals are advised to carefully document patients' medication histories to avoid errors.